Shares of TRANSTHERA-B (02617) surged by more than 14% during the trading session. At the time of writing, the stock is up 8.87%, trading at HK$34.38.

Recently, TRANSTHERA-B (02617) announced the completion of a share placement on May 27, 2026. The placing agent successfully allotted a total of 3.84 million new H shares at a price of HK$40.83 per share to no fewer than six placees.

The gross proceeds from this placement amount to approximately HK$157 million. After deducting placing commissions and other related expenses, the net proceeds are about HK$152 million, resulting in a net issue price of roughly HK$39.66 per share. The company intends to allocate around 90% of the net proceeds, or approximately HK$137 million, towards the development of new indications for its core product, Tinengotinib. The remaining 10%, or about HK$15.21 million, will be used for working capital and general corporate purposes. Following the completion of the placement, the company's shareholding structure has been adjusted, with specific details outlined in the announcement.